The purpose of this bioluminescent biochemical assay is to identify compounds that inhibit the activity of the deubiquitinating enzyme papain-like protease (PLpro) of SARS-CoV or Luciferase. This assay also serves as a counterscreen for a set of previous experiments entitled, "QFRET-based dose response biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro)," (PubChem AID 1890). In this coupled-enzyme assay, test compounds are incubated with recombinant PLpro enzyme and an ubiquitin C-terminal RLRGG-derivatized aminoluciferin substrate, in the presence of luciferase and ATP. PLpro-mediated deubiquitination and cleavage of substrate releases aminoluciferin, which acts as a luciferase substrate, leading to an increase in well luminescence. The light signal is proportional to PLpro activity. As designed, compounds that act as PLpro inhibitors will prevent PLpro-mediated substrate deubiquitination and cleavage, thus preventing release of aminoluciferin, leading to no increase in well luminescence. Compounds were tested in triplicate using a 10-point, 1:3 dilution series starting at a nominal concentration of 60 micromolar. Prior to the start of the assay, a mixture of PLpro peptide substrate and luciferase detection reagent was made up in assay buffer (50mM HEPES, 0.1 mg/ml BSA, 5 mM DTT, 0.5 mM EDTA and 1 mM Magnesium sulfate) at pH 7.5 and incubated for 60 min. The assay was begun by dispensing 2.5 microliters of PLpro enzyme (7.5 nM final concentration) in assay buffer or assay buffer alone into each well of a 1536 microtiter plate. Next, 30 nL of test compound in DMSO, or DMSO alone (0.6% final concentration) was added to the appropriate wells. The plates were then incubated for 10 minutes at room temperature. Next, the enzyme reaction was initiated by dispensing 2.5 microliters of the preincubated mixture containing PLpro peptide substrate and luciferase detection reagent (1 micromolar final substrate concentration). Finally, well luminescence was read on a PerkinElmer Viewlux after 60 minutes of incubation at room temperature.
bao:BAO_0000541 "1706" ; # "is counter assay of" -> "1706"
bao:BAO_0000812 "1859" ; # "has summary assay" -> "1859"
bao:BAO_0000210 bao:BAO_0000032 ; # "has assay stage" -> "secondary assay"
bao:BAO_0001070 bao:BAO_0001064 ; # "has alternate target assay" -> "alternate target assay"
bao:BAO_0000205 bao:BAO_0000217 ; # "has assay format" -> "biochemical format"
bao:BAO_0000205 bao:BAO_0000224 ; # "has assay format" -> "protein format"
bao:BAO_0000205 bao:BAO_0000357 ; # "has assay format" -> "single protein format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002850 bao:BAO_0000534 ; # "has assay readout content" -> "single readout"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BA0_0090012 bao:BAO_0000652 ; # "has participant" -> "protease" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 bao:BAO_0002764 ; # "is bioassay type of" -> "protease activity assay"
bao:BAO_0000212 bao:BAO_0000124 ; # "has assay method" -> "enzyme activity measurement method"
bao:BAO_0000212 bao:BAO_0002593 ; # "has assay method" -> "substrate coupled enzyme activity measurement method"
bao:BAO_0000212 bao:BAO_0002595 ; # "has assay method" -> "luciferin coupled enzyme activity measurement method"
bao:BAO_0000207 bao:BAO_0000045 ; # "has detection method" -> "luminescence method"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Identification of inhibitors of the SARS coronavirus 3C-like Protease (3CLPro)" ; # "screening campaign name" -> "Identification of inhibitors of the SARS coronavirus 3C-like Protease (3CLPro)"
bao:BAO_0002853 "Luminescence-based counterscreen for inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): dose response biochemical high throughput screening assay to identify inhibitors of the papain-like protease (PLpro)" ; # "has assay title" -> "Luminescence-based counterscreen for inhibitors of the SARS coronavirus 3C-like Protease (3CLPro): dose response biochemical high throughput screening assay to identify inhibitors of the papain-like protease (PLpro)"
bao:BAO_0002854 bao:BAO_0000010 ; # "has bioassay type" -> "functional"
bao:BAO_0002867 bao:BAO_0000516 ; # "has assay footprint" -> "1536 well plate"
bao:BAO_0002863 bao:BAO_0000535 ; # "has concentration throughput" -> "multiple concentration"
bao:BAO_0000109 "25 degree celsius" ; # "has temperature value" -> "25 degree celsius"
bao:BAO_0002833 "10 minute" ; # "has incubation time value" -> "10 minute"
bao:BAO_0002857 "minus enzyme" ; # "has signal direction" -> "minus enzyme"
bao:BAO_0000740 bao:BAO_0000156 ; # "has assay control" -> "high signal control"
bao:BAO_0002857 bao:BAO_0000118 ; # "has signal direction" -> "DMSO"
bao:BAO_0000740 bao:BAO_0000168 ; # "has assay control" -> "low signal control"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Valerie Tokars" ; # "material entity assay provider" -> "Valerie Tokars"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Andrew Mesecar" ; # "material entity assay provider" -> "Andrew Mesecar" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000372 ; # "has assay phase characteristic" -> "homogeneous phase"
bao:BAO_0002739 "RLRGG-aminoluciferin" ; # "has substrate" -> "RLRGG-aminoluciferin" || bao:BAO_0003102 bao:BAO_0002030 ; # "has role" -> "coupled substrate"
bao:BA0_0090012 bao:BAO_0000895 ; # "has participant" -> "DTT" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_63247> ; # "has role" -> "reducing agent"
bao:BA0_0090012 bao:BAO_0000776 ; # "has participant" -> "Adenosine triphosphate" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_25078> ; # "has role" -> "luciferin" || bao:BAO_0003102 bao:BAO_00020143 ; # "has role" -> "substrate"
bao:BA0_0090012 "Non-structural protein 3" ; # "has participant" -> "Non-structural protein 3"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_227859> ; # "has organism" -> "SARS coronavirus"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "P0C6X7" ; # "uniprot ID" -> "P0C6X7"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "227859" ; # "NCBI taxonomy ID" -> "227859"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BAO_0002622 bao:BAO_00020127 ; # "has purity value" -> "purified"
bao:BA0_0090012 bao:BAO_0000141 ; # "has participant" -> "Luciferin 4-monooxygenase"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0000261 ; # "has signal direction" -> "signal decrease corresponding to inhibition"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0000648 bao:BAO_0000733 ; # "compound library" -> "MLSMR library"
bao:BAO_0002865 bao:BAO_0001046 ; # "uses detection instrument" -> "ViewLux CCD Imager"
bao:BAO_0000737 bao:BAO_0000297 ; # "has manufacturer" -> "Perkin Elmer" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0000208 bao:BAO_0000190 ; # "has endpoint" -> "IC50"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "2" ; # "PubChem TID" -> "2"
bao:BAO_0002787 "10" ; # "has concentration-point number" -> "10"
bao:BAO_0002845 "3" ; # "has repetition point-number" -> "3"
bao:BAO_0000196 bao:BAO_0000091 ; # "has mode of action" -> "inhibition"
bao:BAO_0002864 bao:BAO_0000533 ; # "has repetition throughput" -> "multiple repetition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Uma" ; # "Annotated by" -> "Uma"
